Fresenius Medical Care (NYSE:FMS) Now Covered by StockNews.com

Equities researchers at StockNews.com began coverage on shares of Fresenius Medical Care (NYSE:FMS) in a report released on Monday. The firm set a “strong-buy” rating on the stock.

Separately, Truist Financial lowered their target price on shares of Fresenius Medical Care from $24.00 to $22.00 and set a “hold” rating for the company in a research note on Wednesday, July 31st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $22.00.

Fresenius Medical Care Stock Down 0.3 %

Shares of NYSE FMS opened at $21.24 on Monday. Fresenius Medical Care has a 52-week low of $16.37 and a 52-week high of $22.76. The business’s 50 day moving average is $19.74 and its two-hundred day moving average is $19.98. The company has a quick ratio of 1.09, a current ratio of 1.46 and a debt-to-equity ratio of 0.45. The firm has a market cap of $12.46 billion, a price-to-earnings ratio of 23.87, a PEG ratio of 1.08 and a beta of 0.90.

Fresenius Medical Care (NYSE:FMS) last posted its quarterly earnings data on Tuesday, July 30th. The company reported $0.38 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.38. Fresenius Medical Care had a return on equity of 5.48% and a net margin of 2.72%. The business had revenue of $5.13 billion for the quarter, compared to analyst estimates of $5.28 billion. Research analysts predict that Fresenius Medical Care will post 1.51 EPS for the current year.

Hedge Funds Weigh In On Fresenius Medical Care

Large investors have recently bought and sold shares of the stock. Wulff Hansen & CO. boosted its stake in shares of Fresenius Medical Care by 1,809.0% during the second quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock worth $6,556,000 after buying an additional 325,439 shares during the period. Triasima Portfolio Management inc. purchased a new position in shares of Fresenius Medical Care during the 1st quarter worth approximately $1,293,000. Veracity Capital LLC boosted its position in Fresenius Medical Care by 172.2% during the first quarter. Veracity Capital LLC now owns 53,023 shares of the company’s stock worth $1,022,000 after acquiring an additional 33,543 shares during the last quarter. Legacy Wealth Asset Management LLC acquired a new stake in Fresenius Medical Care during the first quarter worth approximately $584,000. Finally, Koss Olinger Consulting LLC acquired a new stake in Fresenius Medical Care during the second quarter worth approximately $286,000. Institutional investors and hedge funds own 8.25% of the company’s stock.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.